University of Victoria Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2013
NCT01958593
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

University of Victoria

Active Ingredients

Drugs in Phase 4 Trials (1)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (4)

3,4-Methyl​enedioxy​methamphetamine (1 trial)

hyperimmune bovine colostrum (1 trial)

prenylflavonoids extract (1 trial)

visnadine (1 trial)

Drugs in Other Trials (1)

desloratadine (clarinex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Stress Disorders, Post-Traumatic (Phase 2)

Stress Disorders, Traumatic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6